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Abstract: Human breast cancer is characterized by a high degree of inter-patients heterogeneity in
terms of histology, genomic alterations, gene expression patterns, and metastatic behavior, which
deeply influences individual prognosis and treatment response. The main cause of mortality in breast
cancer is the therapy-resistant metastatic disease, which sets the priority for novel treatment strategies
for these patients. In the present study, we demonstrate that Patient Derived Xenografts (PDXs) that
were obtained from metastatic and therapy-resistant breast cancer samples recapitulate the wide
spectrum of the disease in terms of histologic subtypes and mutational profiles, as evaluated by
whole exome sequencing. We have integrated genomic and transcriptomic data to identify oncogenic
and actionable pathways in each PDX. By taking advantage of primary short-term in vitro cultures
from PDX tumors, we showed their resistance to standard chemotherapy (Paclitaxel), as seen in the
patients. Moreover, we selected targeting drugs and analyzed PDX sensitivity to single agents or to
combination of targeted and standard therapy on the basis of PDX-specific genomic or transcriptomic
alterations. Our data demonstrate that PDXs represent a suitable model to test new targeting drugs or
drug combinations and to prioritize personalized therapeutic regimens for pre-clinal and clinical tests.
Keywords: breast cancer; PDX; oncogenic alterations; personalized therapies
1. Introduction
Breast cancer is the second most common cancer overall and it is the most frequent cancer in women
worldwide [1]. Human breast cancer is well recognized as a heterogeneous disease characterized by
distinct histology, genomic alterations, gene expression patterns, and metastatic behavior, which all
deeply influence prognosis and treatment responses [2–4].
Gene expression profiling has been largely used for breast cancer prognosis, and it has allowed
classification into five intrinsic subtypes with distinct clinical outcomes, which map to immunochemistry-
defined categorization: (1) luminal A (estrogen receptor alpha, ER+, and progesterone receptor positive,
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PgR+; ERBB2 negative, HER2− and negative for the proliferation antigen Ki67; 24% of cases); (2) luminal
B (ER+PgR+, ERBB2(HER2)+ or−, Ki67+; 53%); (3) HER2-type (HER2+, ER−, PgR−; 11%); (4) basal-like
(ER− PgR− HER− triple-negative; 11%); and, (5) Normal-like (ER+ PgR+ HER2−, Ki67-; 8%) [5–7].
This classification is also informative for treatment choices in breast cancer patients. Targeting
the ER by selective ER modulators (SERM) or reducing estradiol with aromatase inhibitors (AI) is the
main treatment of ER+ breast cancer, but endocrine therapy resistance eventually occurs, which leads
to disease progression. Intensive research has been undertaken to decipher the mechanism of SERM
and AI resistance, resulting in the identification of complex pathways, including the modulation of
ER signaling through ESR1 mutation, up regulation of growth factor receptors (HER2, EGFR, FGFR,
IGFIR), alterations of the PI3K-PTEN/AKT/mTOR pathway, and NFkB signaling [8,9]. Patients with
ERBB2-positive tumors receive the ERBB2-targeted antibody or small-molecule inhibitor therapy
combined with chemotherapy [10]. Instead, there are no targeted therapies for the Triple Negative (TN)
subtype, and current regimens involve taxane- or anthracycline-based therapies in either neoadjuvant
or adjuvant settings. Additionally, in this case, the patients frequently progresses to metastatic
disease, but the molecular mechanisms underlying the development of drug resistance remain largely
unclear [11]. Also, drug combination is a widely used approach to decrease side-effects and enhance
the therapeutic efficacy at the same time [12].
The high failure rate in the treatment of breast cancer parallels the high inter-patient genetic and
phenotypic heterogeneity of this tumor, the poor mechanistic understanding of specific vulnerabilities
within individual patients and the lack of preclinical models with predictive value. Thus, there is an
urgent need for experimental models that replicate the heterogeneity of breast cancer at individual
levels in a preclinical setting. Patient-derived xenograft (PDX) models represent the full spectrum of
such heterogeneity in terms of inter-tumor diversity, since they resemble the genetic and transcriptomic
profiles of the patients, and even of intra-tumor variety, where the clonal and cellular diversity of
breast cancer cell populations are shown [13]. As a result, the PDX models exhibit a similar response
to anti-cancer drugs and they represent a powerful tool for translational research. In fact, multiple
therapies can be tested in PDXs that are generated from naïve- and post- treatment patients, faithfully
representing susceptibility and resistance to therapeutic regimens [14]. For these reasons, diverse
academic institutions have developed PDX platforms to investigate mechanisms of acquired resistance,
to identify biomarkers of breast cancer biology, and to design new drug treatments [15].
In the present study, we took advantage of our collection of breast cancer PDXs, which were
created from metastatic breast cancer samples, to uncover tumor frailties by coupling transcriptome
and genomic data. The integration of genetic and transcriptomic information at the level of single
tumors proved to be a valid approach in the identification of specific actionable vulnerabilities, which
could be tested as predictive markers for targeted treatments, alone or in combination.
2. Materials and Methods
2.1. Sample Collection and Ethic Statements
The European Institute of Oncology provided three normal and 23 breast cancer tissues and
blood of breast cancer patients (Milan). Only patients presenting with metastatic disease and with
previous chemotherapy or hormonal therapy were included in the study. Breast tumor/normal tissues
were collected from 2012 to 2015. Investigations have been conducted in accordance with the ethical
standards and according to National and International guidelines. In vivo studies were performed
after approval from our fully authorized animal facility, notification of the experiments to the Ministry
of Health (as required by the Italian Law) (IACUCs Nº 757/2015), and in accordance to European Union
(EU) directive 2010/63. Human tissue biopsies were collected from patients whose informed consent
was obtained in writing according to the policies of the Ethics Committee of the European Institute of
Oncology and regulations of Italian Ministry of Health. The studies were conducted in full compliance
with the Declaration of Helsinki.
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2.2. PDX Tissue Bank Generation
Patients that were enrolled in the study were selected on the basis of highly aggressive metastatic
disease diagnoses (Luminal B, Triple Negative and HER2+ subtypes) and resistance to different lines
of therapy. Patient tumor biopsies from liver (n = 12), lung (n = 8), and axillary lymph node (n = 3)
were transplanted in the fourth mammary gland of female NSG mice (n = 3), together with Matrigel
(Corning #356231). No enzymatic or mechanical tumor dissociation was performed at the first passage
in mice. The animals were monitored for engraftment by routine palpation and the tumors were
harvested when they reached a volume of 0.8 cm3. 12 out of 23 tumors efficiently engrafted in mice at
their first passage. Subsequently, the tumors were digested by enzymatic and mechanical digestion
(Miltenyi Biotec) and 5 × 105–1 × 106 cells were resuspended in Matrigel/PBS (1:1) and orthotopically
transplanted as above in NSG mice (n = 10–15). The same protocol was applied for further passages in
mice, up to three (MBC2, MBC3, MBC4, MBC5, MBC7, MBC10, MBC11, MBC18, MBC21, MBC22 and
MBC26) or four (MBC1) serial transplantations. PDX tumors were also frozen as fragments or cell
suspension for additional experimental purposes or re-transplantation.
2.3. Animals
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from Charles River. Female mice
6–12 weeks old (15–20 g weight) were used for experimental procedures.
2.4. PDX Culture
For in vitro assays, primary two-dimensional (2D) culture of PDX cells (PDXC) were generated by
plating single cell suspension of tumors grown in the animal. The cells were obtained by enzymatic
and mechanical digestion, as described above. PDXCs were maintained in culture for a short period
of time (3 days) in DMEM/F12 (1:1, Lonza/Gibco) supplemented with 10% Fetal Bovine Serum (FBS)
(HyClone, GE Healthcare Life Science, Pittsburgh, PA, USA), 10mM HEPES (Sigma Aldrich-Merck
KGaA, Darmstadt, Germany), 5 µg/mL insulin (Roche, Basel, Switzerland), 0.5 µg/mL hydrocortisone
(Sigma Aldrich-Merck KGaA, Darmstadt, Germany), 10 ng/mL epidermal growth factor (EGF, Tebu-Bio,
Le Perray En Yvelines, France), and 50 ng/mL Cholera Toxin (Sigma Aldrich-Merck KGaA, Darmstadt,
Germany). PDXC were maintained in aforementioned culture conditions to perform drug testing
(see Section 2.7).
2.5. Exome-Sequencing
Genomic DNA (gDNA) of patients’ samples was extracted from frozen (MBC1, MBC3, and MBC5)
or formalin-fixed, paraffin-embedded (FFPE) (MBC2) tissues, containing at least 50% breast cancer cells
tissues, as confirmed by the pathologist. gDNA was also obtained from the blood of matched patients’
tumor tissues (normal counterpart) and xenograft at different passages (all from frozen tissues). gDNA
was prepared while using the Quiagen DNeasy Blood & Tissue Kit, fragmented (Quiagen, Cluj-Napoca,
Romania) and used for Illumina Truseq library construction. Exome-capture was performed using the
SureSelectXT Human All Exon Kit (version 4), according to the manufacturer’s instructions (Agilent
Technologies, Santa Clara, CA, USA). Whole-exome sequencing was performed with the Illumina
Hiseq 2000 (Illumina Inc., San Diego, CA, USA) platform with 101 bp paired-end reads. Sequencing
alignment and subsequent bioinformatic analysis were performed, as previously described [16].
2.6. RNA-Sequencing
Total RNA was extracted from three normal breast tissues and MBC2, MBC7, MBC3, and MBC26
PDXs cells by using Zymo Research RNA extraction kit (Freiburg im Breisgau, Germany), at the latest
passage (PDX3) analyzed for the genomic profile and used to perform drug testing. mRNA purification
and NGS libraries were obtained following Illumina instruction (TruSeq RNA Sample Preparation).
50 bp paired-end RNA-seq reads were aligned to the genome (hg19, GRCh38) while using TopHat2
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2.0.9 [17]. Read counts of each gene were quantified using HTseq [18] and differential analysis was
performed while using DESeq or edgeR Bioconductor packages [19,20]. Gene set enrichment analysis
was performed using GSEA (Gene Set Enrichment Analysis-Broad Institute, Inc. Cambridge, MA,
USA) software v2.2.0 (www.broadinstitute.org/gsea/index.jsp) with GO biological process MSigDB
gene sets using default parameters. Gene sets enriched at False Discovery Rate (FDR) < 0.25 were
considered to be significant.
2.7. Drug Test
Short-term in vitro growth inhibition by drugs in PDX cells was assessed by Cell Titer Glo
(Promega). Briefly, PDXC (obtained from third passage in mice) were thawed and used as primary 2D
in vitro culture. The cells were plated in 96 wells (5000 cells per well) and treated for three days by a
single and continuous exposure to vehicle or increasing concentrations of the following drugs: standard
therapies—Paclitaxel (0.5–2.5 µM), or 4-Hydroxytamoxifen (0.1–12 µM) -targeted therapies -Idasanutlin
(5–15 µM-Selleckchem) or Everolimus (5–25 µM-MCE)—alone or in combination. The inhibitory
concentrations (IC30 and IC50) and percent viability inhibition by fixed doses of the aforementioned
drugs were calculated while using GraphPad Prism software (GraphPad Software Inc. San Diego,
CA, USA).
2.8. Western Blotting
Western blotting was performed after 24 h treatments of PDXC. The cells were lysed in RIPA buffer
and processed, as previously described [21]. Membranes were probed with the following antibodies:
p21 (Santa Cruz Biotechnology, Dallas, TX, Texas), phospho-S6K (p-S6K) (Elabscience, WuHan, China),
phospho-S6 (p-S6) (Cell Signaling Technology, London, UK), γH2Ax (Biolegend, San Diego, CA, USA),
PCNA (Dako, Santa Clara, CA, United States) and cleaved PARP (Cell Signaling Technology, London,
UK). Histone H3 (Abcam, Cambridge, UK) or Vinculin (Sigma Aldrich-Merck KGaA, Darmstadt,
Germany) were used as normalizers. The images were cropped at specific protein band of interest to
improve the clarity of data presentation.
2.9. Statistical Analysis
The data are represented as mean ± SD of biological triplicates. Comparisons between drug
efficacy among groups were assessed by using one-way ANOVA followed by Dunnett Post test.
p ≤ 0.05 and lower were considered significant.
2.10. Data Access
Data sets are available in the Gene Expression Omnibus (GEO) database under accession
number GSE129563.
3. Results
3.1. Breast Cancer PDXs Recapitulate the Biology of the Tumor of Origin
We established a collection of PDXs derived from a specific setting of high incidence relapsed
patients in order to create clinically relevant mouse models of human breast cancer. In details, biopsies
from liver (n = 12), lung (n = 8) and axillary lymph node (n = 3) metastasis were obtained from patients
with different breast cancer subtypes, according to the intrinsic classification in Luminal B; Triple
Negative and HER2+ (Table S1). As first passage, the tumors were transplanted as fragments in the
fourth mammary gland of NSG mice. 12 out of 23 transplanted tumors (52%) efficiently engrafted in
mice: 8/15 Luminal B (LB), 1/3 HER2+, and 3/5 TN (Figure 1A and Table S1). Patients with HER2+
BC were underrepresented in our collection, consistently with their lower patient frequency and
engraftment rate [15]. Successful tumor growth did not correlate with their hormonal status (ER or
PgR), or with metastasis site (liver or lung). LB showed high engraftment capability, as compared to
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published reports [22]. After the first passage, tumors were serially re-transplanted as cell suspension
to obtain the propagation and expansion of each sample in subsequent passages.
Cells 2019, 8, x FOR PEER REVIEW 6 of 19 
 
 
Figure 1. Patient-derived xenograft (PDXs) resemble histologic and mutational features of the 
corresponding patient. Patient Derived Xenografts (PDXs) were obtained by the transplantation of 
patients’ (PTs) tumor in the 4th mammary gland of immunocompromised mice. (A) Doughnut 
represents the number of PDXs divided per subtype (LB: Luminal B; TN: Triple Negative; HER2 
positive: HER2) in the external circle and site of PT’s metastasis in the inner one. (B) Time lines 
indicate the year of the first diagnosis and of the metastasis transplantation in mice to create the 
corresponding PDX. Colored bars indicate the therapeutic regimens administered to each PT. CMF: 
Cyclophosphamide-Methotrexate-Fluorouracil; AC: Adriamycin-Cyclophosphamide; ViFuP: 
Vinorelbine-Fluorouracil-Cisplatin; BEXE: Bevacizumab-Capecitabine-Cyclophosphamide-Erlotinib; 
TAC: Docetaxel-Adriamycin-Cyclophosphamide; ECF: Epirubicin-Cisplatin-Fluorouracil. (C) Whole 
Exome sequencing was performed in four PTs and PDXs. Scatter plots of mutations identified in each 
PT and corresponding PDX at different passages are reported. In the left panels the x-axis indicates 
Variant Allele Frequency (VAF) of the mutations present in the PT and the y-axis indicates those 
present in the paired PDX at first passage (PDX1). In the right panel the x-axis indicates VAF of PDX1 
and the y-axis the VAF of the latest passage obtained for that PDX. Pearson correlations (r) are 
reported. 
  
A
Liver
Lung
LB
HER2
TN
3
1 8
First diagnosis Metastasis
Tamoxifen
LH-RH
Letrozole
Fulvestrant
Vinorelbine
Capecitabine
TaxolExemestane
Bevacizumab
Cyclophosphamide CMF
AC
ViFuP
BEXE
TAC
ECFCisplatin
GemcitabineTrastuzumab
Lapatinib Eribulin
B
2010 2013
2001 2013
20131997
2009 2013
2010 2012
2009 2014
20121994
20122004
20122010
20122001
20122008
20142008
MBC1
MBC2
MBC3
MBC4
MBC5
MBC7
MBC10
MBC11
MBC18
MBC21
MBC22
MBC26
PD
X1
M
BC
1 
(T
N
)
PT
r: 0.86
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
PDX1
PD
X4
r: 0.96
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8 1.0
PDX1
PD
X3
r: 0.76
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
PD
X1
M
BC
2 
(T
N
)
PT
r: 0.71
0.0 0.1 0.2 0.3 0.4 0.5
0.0
0.2
0.4
0.6
0.8
1.0
PDX1
0 0 0 2 0 4 0 6 0 8 1 0
PD
X3
r: 0.89
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
PD
X1
M
BC
3 
(L
B)
PT
0 0 0 2 0 4 0 6 0 8
r: 0.81
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8
PD
X1
M
BC
5 
(L
B)
PT
r: 0.73
0.0 0.2 0.4 0.6 0.8
0.0
0.1
0.2
0.3
0.4
0.5
PDX1
PD
X2
r: 0.71
0.0 0.1 0.2 0.3 0.4 0.5
0.0
0.2
0.4
0.6
0.8
0.6
C
Figure 1. Patient-derived xenograft (PDXs) resemble histologic and mutational features of the
corresponding patient. Patient Derived Xenografts (PDXs) were obtained by the transplantation
of patients’ (PTs) tumor in the 4th mammary gland of immunocompromised mice. (A) Doughnut
represents the number of PDXs divided per subtype (LB: Luminal B; TN: Triple Negative; HER2
positive: HER2) in the external circle and site of PT’s metastasis in the inner one. (B) Time lines
indicate the year of the first diagnosis and of the metastasis transplantation in mice to create
the corresponding PDX. Colored bars indicate the therapeutic regimens administered to each PT.
CMF: Cyclophosphamide-Methotrexate-Fluorouracil; AC: Adriamycin-Cyclophosphamide; ViFuP:
Vinorelbine-Fluorouracil-Cisplatin; BEXE: Bevacizumab-Capecitabine-Cyclophosphamide-Erlotinib;
TAC: Docetaxel-Adriamycin-Cyclophosphamide; ECF: Epirubicin-Cisplatin-Fluorouracil. (C) Whole
Exome sequencing was performed in four PTs and PDXs. Scatter plots of mutations identified in each
PT and corresponding PDX at different passages are reported. In the left panels the x-axis indicates
Variant Allele Frequency (VAF) of the mutations present in the PT and the y-axis indicates those present
in the paired PDX at first passage (PDX1). In the right panel the x-axis indicates VAF of PDX1 and the
y-axis the VAF of the latest passage obtained for that PDX. Pearson correlations (r) are reported.
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Tumors from patients and corresponding PDXs were characterized while using the classical
immunohistochemistry (IHC) markers ER, PgR, HER2, and Ki67. All PDXs retained the same features of
the original tumors (Table S1 and Figure S1A,B for representative staining of TN–MBC7- and LB–MBC22
samples). Cells that were positive for the Human Leukocyte Antigen (HLA) were also Pan-cytokeratin
-positive, thus demonstrating that the growing tumors were of human origin. Expectedly, both the
ductal layer composed of myoepithelial cells and the stroma were HLA-negative and α-SMA positive
(Figure S1C), since human stroma is lost during engraftment and is replaced by the murine one [23].
Moreover, all of the PDXs were derived from patients who developed resistance to endocrine and/or
chemotherapies (Figure 1B).
We performed whole exome sequencing (WES) of four different PDXs (2 TN: MBC1 and MBC2 and
2 LB: MBC3 and MBC5), the corresponding metastasis of origin, and the blood of the patients as normal
counterpart to verify that our PDXs also retained the genomic features of the original tumors (Table
S2). We applied a robust computational pipeline to discriminate human and mouse sequencing-reads
due to variable amounts of murine cells composing the stroma, which allowed for restricting analyses
to human component of our tumor samples [16]. At the genomic level, the PDXs showed a similar
mutational profile in terms of type of mutations (single nucleotide variants; SNVs) and their variant
allele frequency (VAF ≥ 0.05), both with respect to the corresponding primary tumor-sample (Figure 1C
left panels; Pearson correlations: r = 0.71–0.86) and after re-transplantation (Figure 1C, right panels; r
= 0.71–0.96). Snapshots from two different PDXs are reported in Supplementary Figure S1D, showing
the persistence of patient somatic mutations (a missense mutation in MBC1 and a nonsense mutation
in MBC2) or a germline variant in the PDX MBC1 (highlighted in blue). About 3–7% of alterations of
unknown significance were unique to the PT (Table S2). A higher number (about 4–20%) of mutations,
though rarely functionally significant, were present in PDX1, but not in the PT, which suggested a
minimum drift during engraftment, as previously observed [24]. Notably, this was the case for the
missense mutation of the tumor suppressor ARID1A in MBC1 and MBC2 PDXs or for GATA3 insertion
in MBC3 (Table S2). The appearance of new mutations in PDX1 might be the consequence of some
degree of clonal selection during in vivo growth, since mutations of ARID1A are associated with
increased cellular proliferation and have been reported in a variety of human cancers [25]. Finally,
Pearson correlations were extremely high among PDXs at different passages (Supplementary Figure
S1E), supporting high genome stability upon serial transplantation in mice.
Overall, these results suggest that breast cancer PDXs faithfully represent the wide spectrum of
phenotypic and genomic abnormalities of the disease and remain sufficiently stable when re-transplanted.
3.2. Each Metastatic PDX Represents a Unique Genomic Landscape Pattern
Since our four PDXs showed a remarkable degree of genomic fidelity with their tumors of
origin, we sequenced the whole exome of other eight PDXs. The most frequent alterations that were
found in the 12 PDXs were SNVs (mainly missense mutations), followed by Splicing mutations and
Insertion/Deletion (InDels) (Figure 2A), which involved known driver genes and functional pathways
previously described in breast cancer [26] (Figure 2B).
Expectedly, the mutations of TP53 or genes of the PI3K/AKT/mTOR and epithelial-to-mesenchymal
transition (EMT) pathways were found at relatively high frequencies. Additionally, we identified the
alterations of epigenetic targets, such as SWI/SNF related genes (SMARCA2, SMARCA4, SMARCA5)
or histone modifiers (KMT2C or KMT2D), breast cancer-associated oncogenes (MYCN or MAPKs),
or genes that are involved in drug-resistance (ESR1 and PIK3CA/B). The highest mutation rate was
found in the TP53 gene (about 50%) (Figure 2B), which was slightly higher than that reported in breast
cancer metastatic samples (in cBioPortal—http://www.cbioportal.org) (Figure S2A), probably due to
the selective pressure of treatments administered to the patients. Mutation rate in the PIK3CA gene
(about 30%; Figure 2B), instead, was in line with its expected frequency in breast cancer (cBioPortal)
(Figure S2A). One LB PDX (MBC22) showed somatic mutation in the ESR1 gene (Figure 2B), which is
frequently found to be mutated in ER+ metastatic breast cancer and has been correlated with resistance
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to fulvestrant treatment [27]. Six of our 12 PDXs showed alterations in several EMT genes (Figure 2B),
which are known to be implicated in tumor metastasis [28]. When considering the most frequent and
highly actionable mutations (TP53, PIK3CA and ESR1), each PDXs showed a different type of alteration
in terms of protein change, suggesting that each PT/PDX has a unique molecular profile, and predicted
therapeutic response (Figure 2C and Figure S2B).
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IHC staining for TP53 and PIK3CA was performed in samples carrying wild type or mutated
alleles to analyze the effects of the recorded mutations on protein expression. Wild-type TP53 PDXs
(MBC3 and MBC26) showed modest protein expression. PDX samples with mutant TP53 displayed
different patterns, with strong homogeneous (i.e., MBC2) or heterogeneous (i.e., MBC7) staining (Figure
S2C–upper panel). IHC for PIK3CA showed heterogeneity among the samples and only partially
correlated with the mutation per se, since PIK3CA was considerably expressed either in mutant
(MBC22 and MBC7) and WT tumors (MBC3 and MBC26) (Figure S2C–lower panel). This may be due
to alternative mechanisms of PIK3CA activation in samples with wild-type alleles [29].
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3.3. Transcriptional Analysis of PDX Cells Parallels Mutational Profile
Mutations of cancer drivers induce global transcriptional changes [30], which have been shown
to correlate with prognosis and treatment response [31]. Thus, we analyzed the transcriptome of
four breast cancer PDXs, when comparing it to the transcriptome of normal tissue extracted from
three mammary glands. We selected two TN and two LB PDXs harboring somatic mutations of TP53
p.H193R, PIK3CA p.1043I, and AKT1 p.Q85H (MBC7); TP53 p.342* and TSC1 (MBC2); JAK2 p.I702V
(MBC3) and MET p.H60Y and p.D543E (MBC26).
Principal Component Analysis (PCA) clearly segregated the normal from cancer samples
(Figure 3A). LB and TN PDXs displayed distinct expression patterns, supporting their diverse
biological origin (Figure 3A). Indeed, hierarchical clustering of the 1869 most variable genes confirmed
the segregation of Normal breast, LB, and TN breast cancer PDXs (Figure S3A). As expected, the tumors
showed higher heterogeneity than normal tissues, paralleling that observed in the genomic profiles.Cells 2019, 8, x FOR PEER REVIEW 9 of 19 
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Principal component analysis (PCA) score plot of gene expression data from RNA-seq of three normal
breast tissues, two LB, and two TN PDXs (n = 3 replicates) with the two first principal components
(PC1 and PC2) plotted on the x-axis and y-axis, respectively. (B) Representative Gene Set Enrichment
Analysis (GSEA) based on KEGG and HALLMARK databases of each PDX in comparison with
normal breast. Plot size indicates Normalized Enrichment Score (NES) (fill plots up-regulation; empty
plots down-modulation); colors indicate False Discovery Rate (FDR) values. (C) Complementary
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represented with an “x” in each PDX. Heatmap represents LOG2 fold change (FC) values of genes of
the aforementioned pathways.
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When considering the high degree of diversity among PDXs, the transcriptome of each subject
was separately analyzed when comparing it to the average of normal samples to obtain differentially
expressed genes (DEGs) (Table S2). Afterwards, we conducted gene-set enrichment analysis (GSEA) of
the DEGs, based on KEGG and HALLMARK databases. Among the up-regulated genes we observed
enrichment of mTORC1, TP53, and estrogen-response pathways, as well as genes in “Cell cycle”
and “DNA replication”, reflecting the propensity of these cells to activate unrestrained proliferative
functions (Figure 3B and Figure S3B). Among the down-regulated genes, cell adhesion molecules were
strongly down-modulated, as well as apical junctions, which parallels the metastatic origin of the cells
(Figure 3B and Figure S3B).
We compared the transcriptome to the mutational profile in each PDX to search for tumor-specific
pathways that are activated by somatic mutations. First, we confirmed that ESR1 hyper-activation was
exclusively observed in ER+ tumors, while EGFR expression inversely correlated with the hormonal
status (Figure 3C) [32]. ERBB2 and ERBB3 were variably expressed in the four PDXs, while the
transforming growth factor alpha (TGFA) and one of its receptors (EGFR) were highly expressed in
MBC2 (Figure 3C), which suggested that diverse growth factor receptors and proliferative pathways
are activated, depending on the molecular subtype. As supported by GSEA analyses, all the PDXs
exhibited at least one mutation in one of the up-stream regulators of the PI3K/AKT/mTOR pathway:
JAK2 in MBC3, MET in MBC26, TSC1 in MBC2, and AKT and PIK3CA in MBC7, along with protein
over-expression of various genes belonging to the aforementioned pathway (Figure 3C), which suggests
that its specific inhibition can represent an efficient treatment opportunity.
TP53-mutated (-Mut) MBC7 showed the strongest reduction of CDKN2A and PTEN expression,
which is known to inversely correlate with patient prognosis [33,34]. LB PDXs also showed the
hyper-activation of MYC, whose over-expression is associated with aggressive and drug resistant
phenotype [35]. Instead E2F1, whose over-expression correlates with unfavorable outcome and
metastatic disease [36], was equally up-regulated in all of the PDXs (Figure 3C).
Overall, our transcriptomic data provide information on the expression levels of the genes that
are downstream to the identified somatic alterations. Data integration may predict the activation of
oncogenic signals and suggest alternative treatments to target tumor-specific pathways.
3.4. Integration of Genomic and Transcriptomic Profiles Predicts Resistance and Sensitivity to Treatments
Based on the integrated analyses of genomic and transcriptomic profiles (Figure 3C), we used
the four above mentioned PDXs (MCB2, MBC7–as TN and MBC3 and MBC26–as LB), to predict
drug-sensitivity to Everolimus and Tamoxifen (targeting mTOR1 and ESR1, respectively [37,38]) or
drug-resistance to Idasanutlin (inactive in cells with mutated TP53 [39]). We have optimized ex vivo
cultures of cells isolated from PDX tumors in order to use PDXs as a pre-clinical drug testing platform.
First, we analyzed whether our PDXC were indeed resistant to standard therapy as the
corresponding patients to Paclitaxel (PTX), a drug that is used in first-line therapy of TN breast
cancer and as later-line therapy in ER+ metastatic breast cancer [5]. Cells from two TN (MBC2
and MBC7) and two LB (MCB3 and MBC26) PDXs were independently treated with PTX. No PDXs
responded to PTX, as compared to a positive control (MCF10DCIS BC cell line) (Figure S4A), thus
resembling resistance in the corresponding patient upon treatment with PTX or other anti-mitotic agents.
Subsequently, we treated the same PDXC with targeting drugs, as alternative therapies. TP53-Mut
and TP53-WT PDXC were treated with the TP53-MDM2 inhibitor Idasanutlin (IDAS), and cell viability
was evaluated after three days (Figure 4A,B).
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Figure 4. Response of PDXs to alternative drugs suggests efficient therapeutic opportunities. (A–B)
TP53 mutated (Mut) (MBC2 and MBC7) (A) or TP53 wild-type (WT) (MBC3 and MBC26) (B) PDXs
were treated in vitro with increasing concentration of Idasanutlin (IDAS) for three days. Response
of each PDX is reported in terms of cell viability (%) with respect to control (CTRL) sample in n = 3
experiments (mean ± SD). (C–D) The same PDXs classified for their negativity (−) or positivity (+)
to estrogen receptors (ER) were treated for three days with increasing concentrations of Everolimus
(EVER). Cell viability (%) in response to the drug in the ER− (C) or ER+ (D) PDXs is reported in n = 3
experiments (mean ± SD).
As expected, TP53-Mut PDXC (MBC2 and MBC7) showed resistance to IDAS (Figure 4A), while
the TP53-WT cells displayed a modest sensitivity (IC30: 15 µM) (Figure 4B).
We then treated the same PDXC with the mTOR-inhibitor Everolimus (EVER) (Figure 4C,D).
Notably MBC2 (ER-), which carries the mutation of the TSC1 gene, implicated in the mTOR pathway,
showed a good response (IC50 = 10 µM). MBC26 (ER+) and MBC7 (ER−) cells showed a better response
(IC50 = 12–15 µM) with respect to MBC3 (IC50 = 20 µM), although a comparable expression of AKT1
was detected in all three samples (Figure 3C). The ER+ tumors MBC3 and MBC26 were also tested for
their response to Tamoxifen (4-Hydroxytamoxifen, 4-OHT), the elective endocrine therapy for ER+
metastatic tumors [5]. Interestingly, MBC3, which showed the highest expression of ESR1, isplayed
higher sensitivity t 4-OHT tha MBC26 (Figure S4B, MCF-7 used as positive control).
Overall, these data confirm that PDXC reflects the drug resistance responses that were observed
in the corresponding patients, and estimate the sensitivity to standard and alternative agents, thus
validating our integrative analysis approach for the treatment of metastatic breast cancer patients.
Paralleling utational and expression profiles, the response to each drug is different from one PDX to
the other, thus supporting the idea that combining the comprehensive genomic and transcriptomic
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characterization can provide an effective validation step to identify the predictive gene signatures and
therapeutic response.
3.5. Combinatorial Drug Administration Can Prioritize Therapeutic Regimen in Patients
Drug combination has been widely considered to be a valid approach to decreasing the toxicity of
specific drugs and enhancing therapeutic efficacy, exploiting their synergistic effect on tumor growth [12].
A combination of IDAS and PTX was tested in the same PDXC, as above, to uncover potential
sensitization to chemotherapy following TP53 re-activation (Figure 5A). IDAS was administered at
the single concentration of 15 µM, corresponding to IC30 in the sensitive samples (Figure 4B and
Figure S5A), while PTX was added at increasing concentrations from 0.5 to 2.5 µM.
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In two TP53-WT PDXC (the ER+ MBC3 and MBC26) IDAS sensitized cells exposed to scalar
doses of PTX, strongly reducing proliferation with respect to non-sensitized cells (Figure 5A, left panel;
MBC3: p < 0.001; MBC26: p < 0.001). Surprisingly, in two TP53-Mut PDXC (the TN MBC2 and MBC7),
where IDAS per se did not affect cell viability (Figure 4A), we also observed IDAS-PTX synergy, with
the combination inducing a significant reduction of cell viability quantified as more than the sum of
single agents (Figure 5A, right panel; MBC2: p < 0.05; MBC7: p < 0.001).
We then tested the PTX-EVER association. The administration of EVER at a concentration of
10 µM (corresponding to IC30 in MBC7 and IC50 in MBC2; Figure 4C and Figure S5A) almost abolished
cell growth in both TN ER- PDXC also at very low PTX concentrations (Figure 5B, left panel; MBC2:
p < 0.001; MBC7: p < 0.001). On the contrary, EVER (IC50: 20 µM in MBC3 or 15 µM in MBC26) slightly
reduced cell proliferation, above the effect of the corresponding IC50 as single agent, in two ER+ PDXs
(Figure 5B, right panel–Figure S5A). Thus, EVER sensitized breast cancer cells to chemotherapy and
exerted a general greater effect by reducing cell viability only in ER- PDXs.
Finally, we tested the combination of 4-OHT and IDAS or EVER in the two ER+ MBC26 and
MBC3 PDXC. IDAS (15 µM concentration) and 4-OHT strongly reduced cell viability, as compared
to the single 4-OHT administration (MBC26: p < 0.05; MBC3: P not significant—Figure 5C), even if
not significant differences were detected among the standard and combination therapies in the latter
(Figure S5A). EVER (20 µM in MBC3 and 15 µM in MBC26) also reduced cell viability (Figure 5C),
showing additive effects due to the sum of the targeting-agent treatments with endocrine drug (MBC26:
p < 0.05; MBC3: P value is close to statistical significance—Figure S5A).
We used one of our PDX (MBC3) to analyze the target modulation upon treatment (Figure S5B).
An evaluation of drug-dependent effects can inform on the activation of alternative pathways driving
therapy resistance. MBC3 cells were treated for 24h with PTX 5 nM, 4-OHT 1 µM (IC50), IDAS
15 µM (IC30), and EVER 20 µM (IC50) as single administration or in combination. Figure 5D reports
Western blot analysis of several genes that were involved in the molecular pathways targeted by the
drugs. Protein levels were normalized with respect to H3 and compared with control cells (CTRL—no
treatment) (Figure S5C). Moreover, cleaved PARP and PCNA levels were used to analyze apoptosis
and proliferation, respectively. PTX alone only slightly activated DNA damage (γH2Ax) and apoptosis,
as expected in resistant cells. IDAS partially induced phosphorylation of H2Ax [40], which is in line
with its efficacy in this PDX. EVER induced downstream inhibition of mTOR pathway, as shown by
the reduction of phospho-S6K and phospho-S6, and promoted DNA damage (γH2Ax) and moderate
apoptosis. IDAS exerted a synergistic effect with PTX when being administered in combination,
likely activating cell cycle arrest (supported by p21 increase), DNA damage response (γH2Ax), and
apoptosis (cleaved PARP). PCNA levels are increased as a result of DNA damage in the absence of cell
cycling [41].
4-OHT induced p21 increase and cell death in vitro, according to the IC50 used. 4-OHT increased
the phosphorylation levels of S6K and S6, suggesting the activation of mTOR pathway and its
consequent sensitization [42]. As reported elsewhere, mTOR pathway activation may mediate ER
resistance [9]. Notably, when administered in combination, 4-OHT and EVER totally abolished p-S6K
and p-S6 and stimulated DNA damage and apoptosis with increased γH2Ax, PARP cleavage, and the
reduction of p21 levels [43].
Together, these results demonstrate that PDXC can be tested with a large panel of targeting drugs,
alone or in combination, and that agents prioritized by in vitro testing might be successfully translated
in vivo to optimize the therapeutic regimens.
4. Discussion
In this study, we have shown the feasibility of generating breast cancer PDXs that are representative
of the clinical and molecular diversity of the disease. We have demonstrated that PDXs can be extensively
interrogated, both biologically and molecularly, to uncover patient-specific frailties to be therapeutically
exploited. PDXs can be challenged with many candidate-targeted drugs, alone or in combination,
which may be useful for the design of novel personalized treatment approaches.
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The use of PDXs in pre-clinical cancer drug development has become widespread [44]. PDX
models have been successfully adopted in several pre-clinical trials, since the drug response rates in
PDX correlate with those that were observed in clinic. For example, it has been demonstrated that PDXs
faithfully resemble clinical sensitivity to PARP-inhibitor in a pancreatic cancer model obtained from
naïve or treated patients [45] or to arsenic trioxide in relapsed patients with small cell lung cancer [46].
In addition, anti-cancer drugs have been tested for precision medicine approach in ovarian cancer and
leukemia PDXs [47,48]. Collectively, these efforts aim to implement personalized medicine while using
in vitro and ex vivo PDX models. Our biobank involves a distinctive patients’ setting, since the PDXs
were derived from metastatic samples of patients that developed resistance to standard therapeutic
regimens (endocrine and/or chemotherapy). This collection of PDXs offers the unique opportunity
to evaluate new drug options in the context of specific genetic alterations that have evolved under
various therapeutic pressures [49], and they may thus represent the sole opportunities to prolong
patients’ survival.
The comprehensive characterization of histopathological features and somatic genomic alterations
confirmed that these models have a significant level of resemblance with their matched patient samples,
which supports their validity for translational and pre-clinical study [23,24,31,50]. In particular,
the transplantation of the patient’s tumor, either as fragments or dissociated single cells, allowed
for preserving the original histologic characteristics and the vast majority of the unique molecular
sub-clones that compose each individual tumor. The retention of such clonal dynamics is a key aspect
in the evaluation of both tumor biological properties and efficacy of any therapeutic approach, thus
suggesting that PDXs are useful for studying breast cancer biology and drug responses.
Even if the number of our cohort of PDXs is small, genomic profiling of the tumors has revealed
the presence of the most frequent aberrations in breast cancer, and their unique assortment within
individual samples, which suggests that each PDX is representative of the peculiar molecular portfolio of
individual patients that can be used to study drug resistance and disease progression. This encompasses
the idea that treating patients carrying different mutation profiles with the same drug, targeting one of
the driving mutation, or combining few drugs, may be insufficient in optimizing treatment success [51].
Understanding signaling and biological effects due to somatic mutations may contribute to
rationalize drug design and predict patient response [52]. Additionally, previous studies have also
shown a great extent of gene expression changes in metastatic cancer cells and that, in some cases, these
modifications may predict patient survival [53]. Additionally, transcriptome profiles can influence
drug responses. The transcriptome analysis of our PDXs has highlighted the alterations of actionable
pathways (i.e., Estrogen activation, TP53, and PI3K-AKT-mTOR) driving tumorigenic events. Beyond
this, epigenetic modifiers (i.e., Methyltransferase, BET-domain, SWI/SNF, and Lysine Demethylase
members) as well as known long non-coding (lnc) RNAs with a role in breast cancer progression and
prognosis (i.e., MALAT1, HOTAIR1, MEG3) [54,55] have been found to be generally deregulated in
both the LB and TN samples. This finding suggests that our PDX bank could be successfully used to
further analyze patients’ sensitivity to many drugs, targeting different genes and pathways.
By integrating genomic and transcriptomic data, we have proposed a Patient/PDX-centric approach
for the prediction of oncogenic vulnerabilities, thus prioritizing actionable alterations in breast cancer
and cytotoxic drugs as a standard regimen of therapy.
Regarding the response to standard drugs, Paclitaxel resistance was reported to develop in a high
percentage of breast cancer patients (30% of node-negative patients and up to 70% in node-positive BC
patients), with only 23% surviving five years after diagnosis and mainly dying of metastasis spread [56].
Alike, all of the PDXs tested mirror the resistance to paclitaxel, as observed in the corresponding
patients in response to the same drug or to other anti-mitotic agents. For example, MBC26 patient
relapsed to Paclitaxel, MBC3 to Vinorelbine, MBC2, and MBC7 to diverse chemotherapy combinations
(Vinorelbine-, Fluoruracil-, Cisplatin, or Cyclophosphamide- Methotrexate- Fluorouracil). Actually,
the PDXs showed mutations in Tubulin [57] or other tumor suppressors (i.e., TP53, CDKN2A) [58],
whose underlying interaction could justify the onset of anti-mitotic resistance.
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The identification of alternative therapies by means of integrated genomic and transcriptomic
analyses was successfully validated by in vitro drug response. As confirmed by a potent and selective
MDM2-TP53 small-molecule antagonist, Idasanutlin, TP53 mutations is predictive of anti-TP53-drug
resistance [59], while the treatment of cancer cells expressing functional TP53 resulted in the concurrent
transcriptional activation of TP53 downstream genes, cell cycle arrest, and cell death [39].
We defined its actionability as a successful strategy to inhibit cell viability since our model
highlighted the oncogenic role of PI3K-AKT-mTOR pathway alteration. Everolimus is one of the
Rapamycin analogues and acts as an allosteric inhibitor of mTOR1. Genetic alterations, including
mutations and/or amplifications, which activate the PI3K-AKT-mTOR pathway have been successfully
targeted by Everolimus in advanced biliary tract cancer and heavily pretreated metastatic gastric
cancer [60,61]. In our setting, mTOR1 inhibition triggers apoptosis in PDX carrying activating mutations
of the same pathway, confirming that the mTOR1 inhibitor per se can be proposed as an alternative
therapeutic strategy in these patients. Moreover, the response to Tamoxifen induced the best response
in the context of one of the ER+ PDXs (MBC3), likely depending on the cell sensitivity due to
ESR1 expression.
Finally, we combined the standard and targeting drugs, converging on the aforementioned
pathways activation for the onset of resistance mechanisms. In our PDX cells, Paclitaxel and Everolimus
combination induced the best response, since Everolimus reversed chemotherapy-resistance and
greatly increased the apoptotic effects, confirming the additive effects previously described with other
PI3K-mTOR inhibitors, although a significant effect on patients’ survival remains to be elucidated [62,63].
Similar successful combinations of Everolimus and chemotherapy have been described in other
metastatic tumors (i.e., large cell neuroendocrine lung carcinoma, gastroesophageal carcinoma, and
pancreatic cancer) [64–66], thus supporting the relevance of combining targeted and standard drugs
to improve therapeutic efficacy. Concerning the Everolimus-based treatment in ER+ samples, our
PDXs showed a better response in combination with endocrine therapy. The efficacy of this therapeutic
regimen was confirmed by the results that were obtained in the TAMRAD open-label trial, in which the
mTOR inhibitor Everolimus combined with tamoxifen reversed endocrine resistance, thus inducing
substantially longer patients’ survival [67].
Cell death was also obtained by the convergence of TP53 inhibition and the use of genotoxic
agents (i.e., Paclitaxel), either in TP53 -wild type or, surprisingly, -mutant PDXs. In vitro and in vivo
studies have shown that the TP53-inhibitors are less toxic in normal cells [68]. Moreover, the ability of
TP53-small molecules inhibitor to synergize with conventional chemotherapeutic agents has been well
established in other tumor types, as in leukemia, ovarian cancer, and non-small lung cancer [69–71],
thus suggesting the possibility to reduce chemotherapeutic doses in clinical settings minimizing any
potential side-effects in cancer patients [56].
In conclusion, our study supports the idea that the extensive use of PDX models will bring
significant advantages to the clinically predictive value of genomic and transcriptomic biomarkers.
In this approach, screening for a response to classic cytotoxic and alternative-target agents can be
performed and novel combination strategies can be proposed. Moreover, this model is useful for
saving time for therapeutic decision and reflects personalized medicine approach in a preclinical
setting. Further in vivo studies are necessary to take the impact on therapy regimens of either the
microenvironment or the immune system into consideration, since the cells have been grown in
immunocompromised hosts, as well as the possibility of side-effects due to drug toxicities.
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